Clinical Trials Browser

Metastatic Hormone-sensitive Prostate Cancer (mHSPC) × Clear all

NCT07241416 2026-01-30

A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Phase 3 Recruiting

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06010914 2026-01-16

DADOX

Active not recruiting

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07216248 2025-10-29

OPTIMAS

Phase 2 Recruiting

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06392841 2025-10-20

HARMONY

Phase 2 Withdrawn

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)